Sources: LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept - ScienceDirect TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial The novel GIP, GLP1 and glucagon receptor agonist retatrutide delays gastric emptying - Urva - 2023 - Diabetes, Obesity and Metabolism Hemodynamic Effects of Glucagon: A Literature Review | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Hemodynamic Effects of Glucagon: A Literature Review Day 1 - Video 4: GLUCAGON ACTION THE KNOWN UNKNOWNS by Daniel Drucker Wrapping this up, let me shoot from the hip here, this is drug development in action
liraglutide should be discontinued at least one month before Pregnancy and breastfeeding : These medications should be avoided during pregnancy and whilst breastfeeding Mood changes : The MHRA advises monitoring for new or worsening depression or suicidal thoughts Heart rate increases : These medications may cause modest increases in heart rate Patients should contact their GP immediately if experiencing severe abdominal pain, persistent vomiting, signs of allergic reaction, or visual changes
If you miss a week, its best to resume use as soon as possible
Foods to avoid on GLP-1 medications Knowing what to eat matters
See how the pieces fit: review the Weight Management Protocols, or take the Precision Peptide Genetic Test to add the genetic layer before you spend
